» Articles » PMID: 4198107

Metabolism and Excretion of Exogenous Thyrotropin-releasing Hormone in Humans

Overview
Journal J Clin Invest
Specialty General Medicine
Date 1973 Jul 1
PMID 4198107
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

To study the metabolism of thyrotropin-releasing hormone (TRH) in vivo, 400 mug TRH was administered intravenously to eight normal male subjects. Multiple plasma and urine samples were obtained before and after TRH administration. Serum TSH concentrations increased after TRH administration in all subjects. Plasma TRH levels, measured by radioimmunoassay, were undetectable (< 0.4 ng/ml) before TRH administration. Plasma TRH concentrations averaged 33+/-7 ng/ml (mean +/-SEM) 2 min after TRH injection. Thereafter, they decreased rapidly so that the mean plasma TRH level was 2.9 ng/ml 20 min after TRH administration. The fall in plasma TRH levels was linear during this interval. Thereafter TRH levels declined more slowly. The mean half-life (t(1/2)) of TRH was 5.3+/-0.5 min. The mean distribution volume was 15.7+/-3.8 liters, an average of 16.5% of body weight in these subjects. In the urine, 5.5+/-0.9% of the administered TRH was recovered in the 3 h after TRH administration. Of the total urinary TRH recovered, 84.9% was excreted in the first 30 min. These results indicate that TRH is distributed in a large volume, that it is rapidly metabolized and that a significant quantity of administered TRH is excreted in the urine.

Citing Articles

Are thyrotropin-releasing hormone (TRH) and analog taltirelin viable reversal agents of opioid-induced respiratory depression?.

Algera M, Cotten J, van Velzen M, Niesters M, Boon M, Shoham D Pharmacol Res Perspect. 2022; 10(3):e00974.

PMID: 35621218 PMC: 9137104. DOI: 10.1002/prp2.974.


Taltirelin alleviates fatigue-like behavior in mouse models of cancer-related fatigue.

Dougherty J, Wolff B, Cullen M, Saligan L, Gershengorn M Pharmacol Res. 2017; 124:1-8.

PMID: 28720519 PMC: 5587390. DOI: 10.1016/j.phrs.2017.07.012.


Functional characterization of 5-oxoproline transport via SLC16A1/MCT1.

Sasaki S, Futagi Y, Kobayashi M, Ogura J, Iseki K J Biol Chem. 2014; 290(4):2303-11.

PMID: 25371203 PMC: 4303682. DOI: 10.1074/jbc.M114.581892.


Thyrotropin-releasing hormone as a treatment for cancer-related fatigue: a randomized controlled study.

Kamath J, Feinn R, Winokur A Support Care Cancer. 2011; 20(8):1745-53.

PMID: 21947558 DOI: 10.1007/s00520-011-1268-8.


Prodrugs of thyrotropin-releasing hormone and related peptides as central nervous system agents.

Prokai-Tatrai K, Prokai L Molecules. 2009; 14(2):633-54.

PMID: 19214153 PMC: 6253886. DOI: 10.3390/molecules14020633.


References
1.
Odell W, Wilber J, UTIGER R . Studies of thyrotropin physiology by means of radioimmunoassay. Recent Prog Horm Res. 1967; 23:47-85. DOI: 10.1016/b978-1-4831-9826-2.50005-2. View

2.
Redding T, Schally A . Studies on the inactivation of thyrotropin-releasing hormone (TRH). Proc Soc Exp Biol Med. 1969; 131(2):415-20. DOI: 10.3181/00379727-131-33891. View

3.
Redding T, Schally A . The distribution of radioactivity following the administration of labeled thyrotropin-releasing hormone (TRH) in rats and mice. Endocrinology. 1971; 89(4):1075-81. DOI: 10.1210/endo-89-4-1075. View

4.
Anderson M, Bowers C, Kastin A, SCHALCH D, Schally A, Snyder P . Synthetic thyrotropin-releasing hormone. A potent stimulator of thyrotropin secretion in man. N Engl J Med. 1971; 285(23):1279-83. DOI: 10.1056/NEJM197112022852302. View

5.
Lieblich J, UTIGER R . Triiodothyronine radioimmunoassay. J Clin Invest. 1972; 51(1):157-66. PMC: 332941. DOI: 10.1172/JCI106786. View